DK0689428T3 - Forøget cirkulationseffektorpræparat og fremgangsmåde - Google Patents
Forøget cirkulationseffektorpræparat og fremgangsmådeInfo
- Publication number
- DK0689428T3 DK0689428T3 DK94910988T DK94910988T DK0689428T3 DK 0689428 T3 DK0689428 T3 DK 0689428T3 DK 94910988 T DK94910988 T DK 94910988T DK 94910988 T DK94910988 T DK 94910988T DK 0689428 T3 DK0689428 T3 DK 0689428T3
- Authority
- DK
- Denmark
- Prior art keywords
- circulation effect
- increased circulation
- effect preparation
- polymer chains
- effector
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
- Y10S530/812—Peptides or proteins is immobilized on, or in, an organic carrier
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Dispersion Chemistry (AREA)
- Immunology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Transplantation (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Chemical And Physical Treatments For Wood And The Like (AREA)
- Detergent Compositions (AREA)
- Materials For Medical Uses (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/035,443 US6326353B1 (en) | 1993-03-23 | 1993-03-23 | Enhanced circulation effector composition and method |
| PCT/US1994/003103 WO1994021235A1 (en) | 1993-03-23 | 1994-03-22 | Enhanced circulation effector composition and method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK0689428T3 true DK0689428T3 (da) | 1999-09-13 |
Family
ID=21882712
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK94910988T DK0689428T3 (da) | 1993-03-23 | 1994-03-22 | Forøget cirkulationseffektorpræparat og fremgangsmåde |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US6326353B1 (https=) |
| EP (1) | EP0689428B1 (https=) |
| JP (2) | JPH08508256A (https=) |
| AT (1) | ATE175868T1 (https=) |
| AU (1) | AU6368494A (https=) |
| CA (1) | CA2157410C (https=) |
| DE (1) | DE69416116T2 (https=) |
| DK (1) | DK0689428T3 (https=) |
| ES (1) | ES2131190T3 (https=) |
| WO (1) | WO1994021235A1 (https=) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5075222A (en) | 1988-05-27 | 1991-12-24 | Synergen, Inc. | Interleukin-1 inhibitors |
| US6858409B1 (en) | 1988-05-27 | 2005-02-22 | Amgen Inc. | Nucleic acids encoding interleukin-1 inhibitors and processes for preparing interleukin-1 inhibitors |
| US6159460A (en) * | 1988-05-27 | 2000-12-12 | Amgen Inc. | Method for treating interleukin-1 mediated diseases |
| US6180134B1 (en) * | 1993-03-23 | 2001-01-30 | Sequus Pharmaceuticals, Inc. | Enhanced ciruclation effector composition and method |
| GB9509016D0 (en) * | 1995-05-03 | 1995-06-21 | Royal Free Hosp School Med | Tissue entrapment |
| US5919480A (en) * | 1996-06-24 | 1999-07-06 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Liposomal influenza vaccine composition and method |
| JP4771563B2 (ja) | 1996-12-06 | 2011-09-14 | アムジエン・インコーポレーテツド | Ｉｌ−１媒介疾患を処置するためにｉｌ−１インヒビターを使用する組合せ療法 |
| US5827533A (en) * | 1997-02-06 | 1998-10-27 | Duke University | Liposomes containing active agents aggregated with lipid surfactants |
| US6294170B1 (en) | 1997-08-08 | 2001-09-25 | Amgen Inc. | Composition and method for treating inflammatory diseases |
| EP1415998A3 (en) | 1997-02-21 | 2005-11-23 | Genentech, Inc. | Antibody fragment-polymer conjugates and humanized anti-IL-8 monoclonal antibodies |
| US7122636B1 (en) | 1997-02-21 | 2006-10-17 | Genentech, Inc. | Antibody fragment-polymer conjugates and uses of same |
| US6013253A (en) * | 1997-08-15 | 2000-01-11 | Amgen, Inc. | Treatment of multiple sclerosis using consensus interferon and IL-1 receptor antagonist |
| US6468532B1 (en) | 1998-01-22 | 2002-10-22 | Genentech, Inc. | Methods of treating inflammatory diseases with anti-IL-8 antibody fragment-polymer conjugates |
| US7005504B2 (en) | 1998-01-22 | 2006-02-28 | Genentech, Inc. | Antibody fragment-peg conjugates |
| US6458355B1 (en) | 1998-01-22 | 2002-10-01 | Genentech, Inc. | Methods of treating inflammatory disease with anti-IL-8 antibody fragment-polymer conjugates |
| JP4545928B2 (ja) | 1998-04-27 | 2010-09-15 | ジリップ・ファーマ・ビー．ブイ． | 第ｖｉｉｉ因子及び中性リポソームを含有する薬学的組成物 |
| US8106098B2 (en) | 1999-08-09 | 2012-01-31 | The General Hospital Corporation | Protein conjugates with a water-soluble biocompatible, biodegradable polymer |
| US7829074B2 (en) | 2001-10-18 | 2010-11-09 | Nektar Therapeutics | Hydroxypatite-targeting poly(ethylene glycol) and related polymers |
| US7108863B2 (en) * | 2001-03-26 | 2006-09-19 | Alza Corporation | Liposome composition for improved intracellular delivery of a therapeutic agent |
| PH12012502440A1 (en) | 2001-06-26 | 2013-06-17 | Amgen Inc | Antibodies to opgl |
| EP1487493B1 (en) * | 2002-03-01 | 2010-01-20 | The Administrators of The Tulane Educational Fund | Conjugates of cytotoxic agents and biologically active peptides |
| CA2824167C (en) | 2002-09-06 | 2018-09-25 | Amgen Inc. | Therapeutic human anti-il-1r1 monoclonal antibody |
| US20040062748A1 (en) * | 2002-09-30 | 2004-04-01 | Mountain View Pharmaceuticals, Inc. | Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof |
| JP2006517917A (ja) * | 2002-12-19 | 2006-08-03 | アルザ・コーポレーシヨン | 血管新生性の組織増殖の治療方法 |
| WO2004060965A2 (en) | 2002-12-31 | 2004-07-22 | Nektar Therapeutics Al, Corporation | Hydrolytically stable maleimide-terminated polymers |
| US7432331B2 (en) | 2002-12-31 | 2008-10-07 | Nektar Therapeutics Al, Corporation | Hydrolytically stable maleimide-terminated polymers |
| WO2004096140A2 (en) | 2003-04-25 | 2004-11-11 | The Penn State Research Foundation | Method and system for systemic delivery of growth arresting, lipid-derived bioactive compounds |
| EP1654004A2 (en) * | 2003-08-08 | 2006-05-10 | Novo Nordisk A/S | Synthesis and application of new structural well defined branched polymers as conjugating agents for peptides |
| ATE401057T1 (de) * | 2004-10-08 | 2008-08-15 | Alza Corp | Verfahren zur einführung eines lipid-verknüpften teils in eine vorgeformte lipidanordnung mit mikrowellen |
| TW200618820A (en) * | 2004-11-05 | 2006-06-16 | Alza Corp | Liposome formulations of boronic acid compounds |
| US20070014845A1 (en) * | 2005-07-01 | 2007-01-18 | Yuanpeng Zhang | Liposomal delivery vehicle for hydrophobic drugs |
| US20070055199A1 (en) | 2005-08-10 | 2007-03-08 | Gilbert Scott J | Drug delivery device for buccal and aural applications and other areas of the body difficult to access |
| US20070134312A1 (en) * | 2005-09-12 | 2007-06-14 | Hussein Mohamad A | Liposomes for treatment of multiple myeloma |
| AR056806A1 (es) | 2005-11-14 | 2007-10-24 | Amgen Inc | Moleculas quimericas de anticuerpo rankl- pth/ pthrp |
| US20070264322A1 (en) * | 2006-05-10 | 2007-11-15 | Huang Ken S | Method for making liposomes conjugated with temperature-sensitive ligands |
| US7833527B2 (en) | 2006-10-02 | 2010-11-16 | Amgen Inc. | Methods of treating psoriasis using IL-17 Receptor A antibodies |
| EP2217258B1 (en) | 2007-11-14 | 2014-03-26 | General Regeneratives Limited | Use of interleukin-1 receptor antagonist as a myeloprotective agent |
| PT2381964E (pt) | 2008-12-22 | 2014-08-29 | Creabilis S A | Síntese de conjugados poliméricos de compostos de indolocarbazol |
| TW201117824A (en) | 2009-10-12 | 2011-06-01 | Amgen Inc | Use of IL-17 receptor a antigen binding proteins |
| CN101690801B (zh) | 2009-10-26 | 2012-08-01 | 上海交通大学 | 白细胞介素-1受体拮抗剂的用途及其药物组合物 |
| TWI397428B (zh) * | 2009-12-29 | 2013-06-01 | 財團法人工業技術研究院 | 標的第四介白素受體之傳輸系統 |
| DE102010043733A1 (de) | 2010-11-10 | 2012-05-10 | Oxprotect Gmbh | Unbeladene PEGylierte Liposomen zur Verwendung als Arzneimittel zur Prophylaxe und Therapie von hämorrhagischen und thrombo- embolischen Erkrankungen |
| WO2013016220A1 (en) | 2011-07-22 | 2013-01-31 | Amgen Inc. | Il-17 receptor a is required for il-17c biology |
| EP2679236A1 (de) * | 2012-06-29 | 2014-01-01 | Zentrum für biomedizinische Technologie der Donau- Universität Krems | Dosierungsanleitung für endotoxinbindende Lipopeptide |
| WO2014050509A1 (ja) * | 2012-09-25 | 2014-04-03 | テルモ株式会社 | リポソームおよびリポソーム製剤 |
| AU2014251388B2 (en) | 2013-04-12 | 2017-03-30 | Evox Therapeutics Limited | Therapeutic delivery vesicles |
| US20160000936A1 (en) | 2014-06-10 | 2016-01-07 | Abbvie Inc. | Biomarkers for inflammatory disease and methods of using same |
| GB201417589D0 (en) | 2014-10-06 | 2014-11-19 | Cantab Biopharmaceuticals Patents Ltd | Pharmaceutical Formulations |
| US10041044B2 (en) | 2016-07-29 | 2018-08-07 | Trustees Of Boston University | Age-associated clonal hematopoiesis accelerates cardio-metabolic disease development |
| WO2020035482A1 (en) | 2018-08-13 | 2020-02-20 | Iltoo Pharma | Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof |
| CN111217993B (zh) * | 2018-11-26 | 2022-05-20 | 沈阳药科大学 | 一种聚乙二醇化酚红及其制备方法和用途 |
| EP4526469A1 (en) | 2022-05-16 | 2025-03-26 | Institut National de la Santé et de la Recherche Médicale | Methods for assessing the exhaustion of hematopoietic stems cells induced by chronic inflammation |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) * | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4948590A (en) * | 1987-06-09 | 1990-08-14 | Yale University | Avidin or streptavidin conjugated liposomes |
| AU5858690A (en) * | 1989-06-14 | 1991-01-08 | Cetus Corporation | Polymer/antibiotic conjugate |
| US5013556A (en) * | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| ATE125697T1 (de) * | 1991-02-14 | 1995-08-15 | Baxter Int | Koppelung des wachstumshormons an liposomen. |
| JP3220180B2 (ja) * | 1991-05-23 | 2001-10-22 | 三菱化学株式会社 | 薬剤含有タンパク質結合リポソーム |
-
1993
- 1993-03-23 US US08/035,443 patent/US6326353B1/en not_active Expired - Lifetime
-
1994
- 1994-03-22 CA CA002157410A patent/CA2157410C/en not_active Expired - Fee Related
- 1994-03-22 AU AU63684/94A patent/AU6368494A/en not_active Abandoned
- 1994-03-22 ES ES94910988T patent/ES2131190T3/es not_active Expired - Lifetime
- 1994-03-22 EP EP94910988A patent/EP0689428B1/en not_active Expired - Lifetime
- 1994-03-22 WO PCT/US1994/003103 patent/WO1994021235A1/en not_active Ceased
- 1994-03-22 JP JP6521332A patent/JPH08508256A/ja active Pending
- 1994-03-22 AT AT94910988T patent/ATE175868T1/de not_active IP Right Cessation
- 1994-03-22 DK DK94910988T patent/DK0689428T3/da active
- 1994-03-22 DE DE69416116T patent/DE69416116T2/de not_active Expired - Fee Related
-
2004
- 2004-12-14 JP JP2004362085A patent/JP2005097320A/ja not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| ES2131190T3 (es) | 1999-07-16 |
| CA2157410C (en) | 1999-12-07 |
| ATE175868T1 (de) | 1999-02-15 |
| DE69416116T2 (de) | 1999-06-24 |
| US6326353B1 (en) | 2001-12-04 |
| CA2157410A1 (en) | 1994-09-29 |
| AU6368494A (en) | 1994-10-11 |
| JPH08508256A (ja) | 1996-09-03 |
| JP2005097320A (ja) | 2005-04-14 |
| EP0689428B1 (en) | 1999-01-20 |
| WO1994021235A1 (en) | 1994-09-29 |
| DE69416116D1 (de) | 1999-03-04 |
| EP0689428A1 (en) | 1996-01-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK0689428T3 (da) | Forøget cirkulationseffektorpræparat og fremgangsmåde | |
| DE69435330D1 (de) | Verwendung von Botulinumtoxin Typ B zur Herstellung eines Medikaments zur Behandlung von Muskelkrämpfen | |
| FI964339L (fi) | Glukaanien entsyymikäsittely | |
| DE59603216D1 (de) | Esterquats und ihre Verwendung zur Herstellung von oberflächenaktiven Mitteln, insbesondere zur Haar- und Körperpflege | |
| DE69618176D1 (de) | Weiches behandeltes tissue | |
| DE68924026D1 (de) | Biosensor und dessen herstellung. | |
| NZ334190A (en) | Method for improved selectivity in photo-activation of molecular agents | |
| DE69636147D1 (de) | Verfahren zur herstellung von phosphorothioat-oligomeren | |
| DE69524864D1 (de) | 4-amino-derivate der mycophenolsäure mit immun suppressiver wirkung | |
| DE60045010D1 (de) | Behandlung von infektionen des verdauungstrakts mit enzymen | |
| DE68908030D1 (de) | Katheter und methoden zur herstellung. | |
| ID17771A (id) | Pemindahan ruang-ruang lift di antara lorong-lorong yang tidak bersebelahan | |
| NO891823L (no) | Overflatebehandling av haardt vev. | |
| DE69633985D1 (de) | Behandlung von Chromoxid und dessen Verwendung in der katalytischen Herstellung von Vinylfluorid | |
| NO982727D0 (no) | PGE-holdige lyofiliserte liposomer for anvendelse i behandling av erektil dysfunksjon | |
| ATE246518T1 (de) | Egr-1 zur herstellung eines medikamentes zur behandlung von wunden | |
| DE69626816D1 (de) | Verwendung von selegilin zur behandlung von gehörverlust bei säugetieren | |
| DE69619051D1 (de) | Behandlung von Füllstoffen mit Oxasilacycloalkanen | |
| DE69818809D1 (de) | Verfahren zur behandlung von narbengewebe | |
| DE69524388D1 (de) | 4-amino-6-substituierte mycophenolsäurederivate mit immunsuppressiver wirkung | |
| KR900011940A (ko) | 폴리실록산으로 처리한 부드러운 티슈종이의 제조방법 | |
| AU7053894A (en) | Enzymatic rna molecules and their application in the treatment of fibrosis and fibrous tissue disease | |
| EP0329948A3 (de) | Verwendung von Betablockern zur Behandlung der Progression der kindlichen Achsenmyopie | |
| ITRM930818A0 (it) | Procedimento per la produzione in piante di anticorpi ingegnerizzati, anticorpi prodotti e loro uso in diagnosi e terapia. | |
| DE69607595D1 (de) | Herstellung von optisch aktiven aliphetischen carbonsäuren |